Comparative Pharmacology
Head-to-head clinical analysis: ROXICODONE versus ZIPAN 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ROXICODONE versus ZIPAN 50.
ROXICODONE vs ZIPAN-50
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Oxycodone is a full opioid agonist with high affinity for mu-opioid receptors, also binding to kappa and delta receptors. It acts primarily on the central nervous system and gastrointestinal tract.
ZIPAN-50 (zinc acetate) is a dietary supplement that provides zinc, an essential trace element. Zinc acts as a cofactor for numerous enzymes, including those involved in DNA synthesis, cell division, and immune function. It also stabilizes cell membranes and has antioxidant properties.
5-15 mg orally every 4-6 hours as needed for pain; immediate-release formulation. Maximum 60 mg total daily dose for opioid-naive patients.
50 mg orally once daily
None Documented
None Documented
3.5-5 hours for immediate-release; 4.5-5.5 hours for extended-release. Accumulation may occur with repeated dosing, especially in elderly or hepatic impairment.
Terminal elimination half-life is 4 hours (range 3-5 hours) in patients with normal renal function; prolonged to 12-18 hours in severe renal impairment (CrCl <30 mL/min).
Renal excretion: 70-80% as unchanged drug and metabolites (oxymorphone, noroxycodone); fecal: 10-20%.
Renal excretion of unchanged drug accounts for approximately 60%, with 30% as glucuronide conjugate. Biliary/fecal elimination contributes 10%.
Category C
Category C
Opioid Analgesic
Opioid Analgesic